If the promise of biosimilars is only savings for the government, rather than savings and wider access, what is the point from a patient perspective? The one-dimensional focus on savings is an obvious policy failure. …
Opportunity #1 - biosimilar policy failure has become impossible to ignore
August 18, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
The regulator that deleted the truth from its answers now wants to police the media
October 1, 2026 - - Latest News -
By the TGA's own test, the Health Minister's press releases are advertising
October 1, 2026 - - Latest News -
Eczema patients who don't respond to steroids get subsidised access to ointment
October 1, 2026 - - Latest News -
Vitrafy takes its frozen platelet push to America's Midwest
September 30, 2026 - - Australian Biotech -
Paradigm Biopharmaceuticals enters voluntary administration after Phase 3 setback
September 30, 2026 - - Australian Biotech -
FDA fast tracks Telix scan that could spare men prostate biopsies
September 30, 2026 - - Australian Biotech -
Australian broadcast personality reveals the scars shingles left behind
September 30, 2026 - - Latest News